Cardiac metabolism — A promising therapeutic target for heart failure

Pharmacology and Therapeutics

Volumn 182, Issue , 2018, Pages 95-114

  Noordali, Hannah ^a   Loudon, Brodie L ^b   Frenneaux, Michael P ^b   Madhani, Melanie ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Cardiac metabolism; Heart failure; Heart failure with preserved ejection fraction (HFpEF); Heart failure with reduced ejection fraction (HFrEF); Metabolic modulation

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE; DICHLOROACETIC ACID; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KETONE; MALONYL COENZYME A DECARBOXYLASE; UBIDECARENONE;

CITRIC ACID CYCLE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GLUCOSE METABOLISM; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART MUSCLE METABOLISM; HUMAN; OXIDATIVE PHOSPHORYLATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; CARDIAC MUSCLE; DRUG EFFECT; ENERGY METABOLISM; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ENERGY METABOLISM; HEART FAILURE; HUMANS; MOLECULAR TARGETED THERAPY; MYOCARDIUM;

EID: 85028838904     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2017.08.001     Document Type: Review

References (298)

1. Abozguia, K., Elliott, P., McKenna, W., Phan, T.T., Nallur-Shivu, G., Ahmed, I. et al., Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122 (2010), 1562–1569.
2. Akkafa, F., Halil Altiparmak, I., Erkus, M.E., Aksoy, N., Kaya, C., Ozer, A. et al., Reduced SIRT1 expression correlates with enhanced oxidative stress in compensated and decompensated heart failure. Redox Biology 6 (2015), 169–173.
3. Akki, A., Smith, K., Seymour, A.M., Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Molecular and Cellular Biochemistry 311 (2008), 215–224.
4. Arany, Z., Novikov, M., Chin, S., Ma, Y., Rosenzweig, A., Spiegelman, B.M., Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proceedings of the National Academy of Sciences of the United States of America 103 (2006), 10086–10091.
5. Armstrong, M.L., Proceedings: A comparative study of perhexiline, beta-adrenergic blocking agents and placebos in the management of angina pectoris. Postgraduate Medical Journal 49:Suppl. 3 (1973), 108–112.
6. Ashrafian, H., Frenneaux, M.P., Opie, L.H., Metabolic mechanisms in heart failure. Circulation 116 (2007), 434–448.
7. Ashrafian, H., Horowitz, J.D., Frenneaux, M.P., Perhexiline. Cardiovascular Drug Reviews 25 (2007), 76–97.
8. Atherton, J.J., Moore, T.D., Lele, S.S., Thomson, H.L., Galbraith, A.J., Belenkie, I. et al., Diastolic ventricular interaction in chronic heart failure. Lancet 349 (1997), 1720–1724.
9. Aubert, G., Martin, O.J., Horton, J.L., Lai, L., Vega, R.B., Leone, T.C. et al., The failing heart relies on ketone bodies as a fuel. Circulation 133 (2016), 698–705.
10. Azzu, V., Brand, M.D., The on-off switches of the mitochondrial uncoupling proteins. Trends in Biochemical Sciences 35 (2010), 298–307.
11. Balgi, A.D., Fonseca, B.D., Donohue, E., Tsang, T.C., Lajoie, P., Proud, C.G. et al., Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PloS One, 4, 2009, e7124.
12. Barger, P.M., Brandt, J.M., Leone, T.C., Weinheimer, C.J., Kelly, D.P., Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. The Journal of Clinical Investigation 105 (2000), 1723–1730.
13. Barlaka, E., Gorbe, A., Gaspar, R., Paloczi, J., Ferdinandy, P., Lazou, A., Activation of PPARbeta/delta protects cardiac myocytes from oxidative stress-induced apoptosis by suppressing generation of reactive oxygen/nitrogen species and expression of matrix metalloproteinases. Pharmacological Research 95-96 (2015), 102–110.
14. Bartha, E., Solti, I., Kereskai, L., Lantos, J., Plozer, E., Magyar, K. et al., PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovascular Research 83 (2009), 501–510.
15. Bayeva, M., Gheorghiade, M., Ardehali, H., Mitochondria as a therapeutic target in heart failure. Journal of the American College of Cardiology 61 (2013), 599–610.
16. Beadle, R., Frenneaux, M., Magnetic resonance spectroscopy in myocardial disease. Expert Review of Cardiovascular Therapy 8 (2010), 269–277.
17. Beadle, R.M., Williams, L.K., Kuehl, M., Bowater, S., Abozguia, K., Leyva, F. et al., Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. JACC Heart Failure 3 (2015), 202–211.
18. Bedi, K.C. Jr., Snyder, N.W., Brandimarto, J., Aziz, M., Mesaros, C., Worth, A.J. et al., Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133 (2016), 706–716.
19. Beer, M., Seyfarth, T., Sandstede, J., Landschutz, W., Lipke, C., Kostler, H. et al., Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. Journal of the American College of Cardiology 40 (2002), 1267–1274.
20. Bersin, R.M., Wolfe, C., Kwasman, M., Lau, D., Klinski, C., Tanaka, K. et al., Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. Journal of the American College of Cardiology 23 (1994), 1617–1624.
21. Bing, R.J., Siegel, A., Ungar, I., Gilbert, M., Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. The American Journal of Medicine 16 (1954), 504–515.
22. Bockhardt, H., Drenckhahn, D., Lullmann-Rauch, R., Amiodarone-induced lipidosis-like alterations in ocular tissues of rats. Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie 207 (1978), 91–96.
23. Borbely, A., Falcao-Pires, I., van Heerebeek, L., Hamdani, N., Edes, I., Gavina, C. et al., Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circulation Research 104 (2009), 780–786.
24. Borbely, A., van der Velden, J., Papp, Z., Bronzwaer, J.G., Edes, I., Stienen, G.J. et al., Cardiomyocyte stiffness in diastolic heart failure. Circulation 111 (2005), 774–781.
25. Borlaug, B.A., Kass, D.A., Ventricular-vascular interaction in heart failure. Cardiology Clinics 29 (2011), 447–459.
26. Borlaug, B.A., Koepp, K.E., Melenovsky, V., Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology 66 (2015), 1672–1682.
27. Borlaug, B.A., Lam, C.S., Roger, V.L., Rodeheffer, R.J., Redfield, M.M., Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. Journal of the American College of Cardiology 54 (2009), 410–418.
28. Borlaug, B.A., Melenovsky, V., Koepp, K.E., Inhaled sodium nitrite improves rest and exercise hemodynamics in heart failure with preserved ejection fraction. Circulation Research 119 (2016), 880–886.
29. Borlaug, B.A., Melenovsky, V., Redfield, M.M., Kessler, K., Chang, H.J., Abraham, T.P. et al., Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. Journal of the American College of Cardiology 50 (2007), 1570–1577.
30. Borlaug, B.A., Nishimura, R.A., Sorajja, P., Lam, C.S., Redfield, M.M., Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circulation. Heart Failure 3 (2010), 588–595.
31. Borlaug, B.A., Paulus, W.J., Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment. European Heart Journal 32 (2011), 670–679.
32. Bristow, M.R., Ginsburg, R., Minobe, W., Cubicciotti, R.S., Sageman, W.S., Lurie, K. et al., Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. The New England Journal of Medicine 307 (1982), 205–211.
33. de Brouwer, K.F., Degens, H., Aartsen, W.M., Lindhout, M., Bitsch, N.J., Gilde, A.J. et al., Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice. Journal of Molecular and Cellular Cardiology 40 (2006), 838–845.
34. Bugger, H., Schwarzer, M., Chen, D., Schrepper, A., Amorim, P.A., Schoepe, M. et al., Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure. Cardiovascular Research 85 (2010), 376–384.
35. Bui, A.L., Horwich, T.B., Fonarow, G.C., Epidemiology and risk profile of heart failure. Nature Reviews. Cardiology 8 (2011), 30–41.
36. Bursi, F., Weston, S.A., Redfield, M.M., Jacobsen, S.J., Pakhomov, S., Nkomo, V.T. et al., Systolic and diastolic heart failure in the community. JAMA 296 (2006), 2209–2216.
37. Calcutt, N.A., Lopez, V.L., Bautista, A.D., Mizisin, L.M., Torres, B.R., Shroads, A.L. et al., Peripheral neuropathy in rats exposed to dichloroacetate. Journal of Neuropathology and Experimental Neurology 68 (2009), 985–993.
38. Carley, A.N., Lewandowski, E.D., Triacylglycerol turnover in the failing heart. Biochimica et Biophysica Acta 1860 (2016), 1492–1499.
39. Cave, A.C., Ingwall, J.S., Friedrich, J., Liao, R., Saupe, K.W., Apstein, C.S. et al., ATP synthesis during low-flow ischemia: Influence of increased glycolytic substrate. Circulation 101 (2000), 2090–2096.
40. Chaitman, B.R., Pepine, C.J., Parker, J.O., Skopal, J., Chumakova, G., Kuch, J. et al., Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 291 (2004), 309–316.
41. Chan, A.Y., Soltys, C.L., Young, M.E., Proud, C.G., Dyck, J.R., Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. The Journal of Biological Chemistry 279 (2004), 32771–32779.
42. Chance, B., Im, J., Nioka, S., Kushmerick, M., Skeletal muscle energetics with PNMR: Personal views and historic perspectives. NMR in Biomedicine 19 (2006), 904–926.
43. 2 sensing. The Journal of Biological Chemistry 275 (2000), 25130–25138.
44. Chandran, K., Aggarwal, D., Migrino, R.Q., Joseph, J., McAllister, D., Konorev, E.A. et al., Doxorubicin inactivates myocardial cytochrome c oxidase in rats: Cardioprotection by Mito-Q. Biophysical Journal 96 (2009), 1388–1398.
45. Chen, C.H., Fetics, B., Nevo, E., Rochitte, C.E., Chiou, K.R., Ding, P.A. et al., Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. Journal of the American College of Cardiology 38 (2001), 2028–2034.
46. Chen, T., Liu, J., Li, N., Wang, S., Liu, H., Li, J. et al., Mouse SIRT3 attenuates hypertrophy-related lipid accumulation in the heart through the deacetylation of LCAD. PloS One, 10, 2015, e0118909.
47. Chen, A.D., Zhang, S.J., Yuan, N., Xu, Y., De, W., Gao, X.Y. et al., Angiotensin AT1 receptors in paraventricular nucleus contribute to sympathetic activation and enhanced cardiac sympathetic afferent reflex in renovascular hypertensive rats. Experimental Physiology 96 (2011), 94–103.
48. Cheng, J.F., Chen, M., Wallace, D., Tith, S., Haramura, M., Liu, B. et al., Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. Journal of Medicinal Chemistry 49 (2006), 1517–1525.
49. Chess, D.J., Khairallah, R.J., O'Shea, K.M., Xu, W., Stanley, W.C., A high-fat diet increases adiposity but maintains mitochondrial oxidative enzymes without affecting development of heart failure with pressure overload. American Journal of Physiology. Heart and Circulatory Physiology 297 (2009), H1585–1593.
50. Chokshi, A., Drosatos, K., Cheema, F.H., Ji, R., Khawaja, T., Yu, S. et al., Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 125 (2012), 2844–2853.
51. Chong, C.R., Chan, W.P., Nguyen, T.H., Liu, S., Procter, N.E., Ngo, D.T. et al., Thioredoxin-interacting protein: Pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and diabetes. Cardiovascular Drugs and Therapy 28 (2014), 347–360.
52. Chong, C.R., Sallustio, B., Horowitz, J.D., Drugs that affect cardiac metabolism: Focus on perhexiline. Cardiovascular Drugs and Therapy 30 (2016), 399–405.
53. Circu, M.L., Aw, T.Y., Reactive oxygen species, cellular redox systems, and apoptosis. Free Radical Biology & Medicine 48 (2010), 749–762.
54. Cole, P.L., Beamer, A.D., McGowan, N., Cantillon, C.O., Benfell, K., Kelly, R.A. et al., Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 81 (1990), 1260–1270.
55. Cotter, D.G., Schugar, R.C., Crawford, P.A., Ketone body metabolism and cardiovascular disease. American Journal of Physiology. Heart and Circulatory Physiology 304 (2013), H1060–1076.
56. Cowley, A.W. Jr., Abe, M., Mori, T., O'Connor, P.M., Ohsaki, Y., Zheleznova, N.N., Reactive oxygen species as important determinants of medullary flow, sodium excretion, and hypertension. American Journal of Physiology. Renal Physiology 308 (2015), F179–197.
57. 13C metabolic MRI of the human heart: Initial experience. Circulation Research 119 (2016), 1177–1182.
58. Dai, D.F., Chen, T., Szeto, H., Nieves-Cintron, M., Kutyavin, V., Santana, L.F. et al., Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. Journal of the American College of Cardiology 58 (2011), 73–82.
59. Dai, D.F., Hsieh, E.J., Chen, T., Menendez, L.G., Basisty, N.B., Tsai, L. et al., Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides. Circulation. Heart Failure 6 (2013), 1067–1076.
60. Dai, D.F., Hsieh, E.J., Liu, Y., Chen, T., Beyer, R.P., Chin, M.T. et al., Mitochondrial proteome remodelling in pressure overload-induced heart failure: The role of mitochondrial oxidative stress. Cardiovascular Research 93 (2012), 79–88.
61. Davies, B.J., Coller, J.K., James, H.M., Gillis, D., Somogyi, A.A., Horowitz, J.D. et al., Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. British Journal of Clinical Pharmacology 57 (2004), 456–463.
62. De Angelis, A., Cappetta, D., Piegari, E., Rinaldi, B., Ciuffreda, L.P., Esposito, G. et al., Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction. International Journal of Cardiology 217 (2016), 69–79.
63. De Meyer, G.R., De Keulenaer, G.W., Martinet, W., Role of autophagy in heart failure associated with aging. Heart Failure Reviews 15 (2010), 423–430.
64. De Tombe, P.P., Jones, S., Burkhoff, D., Hunter, W.C., Kass, D.A., Ventricular stroke work and efficiency both remain nearly optimal despite altered vascular loading. The American Journal of Physiology 264 (1993), H1817–1824.
65. Dhakal, B.P., Malhotra, R., Murphy, R.M., Pappagianopoulos, P.P., Baggish, A.L., Weiner, R.B. et al., Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: The role of abnormal peripheral oxygen extraction. Circulation. Heart Failure 8 (2015), 286–294.
66. Doehner, W., Frenneaux, M., Anker, S.D., Metabolic impairment in heart failure: The myocardial and systemic perspective. Journal of the American College of Cardiology 64 (2014), 1388–1400.
67. Doenst, T., Nguyen, T.D., Abel, E.D., Cardiac metabolism in heart failure: Implications beyond ATP production. Circulation Research 113 (2013), 709–724.
68. Doenst, T., Pytel, G., Schrepper, A., Amorim, P., Farber, G., Shingu, Y. et al., Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovascular Research 86 (2010), 461–470.
69. Dyck, J.R., Cheng, J.F., Stanley, W.C., Barr, R., Chandler, M.P., Brown, S. et al., Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circulation Research 94 (2004), e78–84.
70. Eurich, D.T., Majumdar, S.R., McAlister, F.A., Tsuyuki, R.T., Johnson, J.A., Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28 (2005), 2345–2351.
71. Eurich, D.T., Tsuyuki, R.T., Majumdar, S.R., McAlister, F.A., Lewanczuk, R., Shibata, M.C. et al., Metformin treatment in diabetes and heart failure: When academic equipoise meets clinical reality. Trials, 10, 2009, 12.
72. Fath-Ordoubadi, F., Beatt, K.J., Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: An overview of randomized placebo-controlled trials. Circulation 96 (1997), 1152–1156.
73. Feng, G., Yang, Y., Chen, J., Wu, Z., Zheng, Y., Li, W. et al., Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure. American Journal of Translational Research 8 (2016), 1295–1301.
74. Fillmore, N., Lopaschuk, G.D., Targeting mitochondrial oxidative metabolism as an approach to treat heart failure. Biochimica et Biophysica Acta 1833 (2013), 857–865.
75. Fotino, A.D., Thompson-Paul, A.M., Bazzano, L.A., Effect of coenzyme Q(1)(0) supplementation on heart failure: A meta-analysis. The American Journal of Clinical Nutrition 97 (2013), 268–275.
76. Fragasso, G., Palloshi, A., Puccetti, P., Silipigni, C., Rossodivita, A., Pala, M. et al., A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. Journal of the American College of Cardiology 48 (2006), 992–998.
77. Fukushima, A., Lopaschuk, G.D., Acetylation control of cardiac fatty acid beta-oxidation and energy metabolism in obesity, diabetes, and heart failure. Biochimica et Biophysica Acta 1862 (2016), 2211–2220.
78. Gandhi, S.K., Powers, J.C., Nomeir, A.M., Fowle, K., Kitzman, D.W., Rankin, K.M. et al., The pathogenesis of acute pulmonary edema associated with hypertension. The New England Journal of Medicine 344 (2001), 17–22.
79. Gatto, G.J. Jr., Ao, Z., Kearse, M.G., Zhou, M., Morales, C.R., Daniels, E. et al., NADPH oxidase-dependent and -independent mechanisms of reported inhibitors of reactive oxygen generation. Journal of Enzyme Inhibition and Medicinal Chemistry 28 (2013), 95–104.
80. Gavin, A.D., Struthers, A.D., Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 91 (2005), 749–753.
81. Gehmlich, K., Dodd, M.S., Allwood, J.W., Kelly, M., Bellahcene, M., Lad, H.V. et al., Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy. Molecular BioSystems 11 (2015), 564–573.
82. Giblett, J.P., Axell, R.G., White, P.A., Clarke, S.J., McCormick, L., Read, P.A. et al., Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: Mechanistic insights from human supply and demand ischemia studies. Cardiovascular Diabetology, 15, 2016, 99.
83. Gibson, C.M., Giugliano, R.P., Kloner, R.A., Bode, C., Tendera, M., Janosi, A. et al., EMBRACE STEMI study: A Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. European Heart Journal 37 (2016), 1296–1303.
84. Gilde, A.J., van der Lee, K.A., Willemsen, P.H., Chinetti, G., van der Leij, F.R., van der Vusse, G.J. et al., Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circulation Research 92 (2003), 518–524.
85. Gillebert, T.C., Leite-Moreira, A.F., De Hert, S.G., Relaxation-systolic pressure relation. A load-independent assessment of left ventricular contractility. Circulation 95 (1997), 745–752.
86. Graham, D., Huynh, N.N., Hamilton, C.A., Beattie, E., Smith, R.A., Cocheme, H.M. et al., Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 54 (2009), 322–328.
87. Gu, X.S., Wang, Z.B., Ye, Z., Lei, J.P., Li, L., Su, D.F. et al., Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. Genetics and Molecular Research 13 (2014), 323–335.
88. Guazzi, M., Borlaug, B.A., Pulmonary hypertension due to left heart disease. Circulation 126 (2012), 975–990.
89. Gundewar, S., Calvert, J.W., Jha, S., Toedt-Pingel, I., Ji, S.Y., Nunez, D. et al., Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circulation Research 104 (2009), 403–411.
90. Guo, Y., Fan, Y., Zhang, J., Lomberk, G.A., Zhou, Z., Sun, L. et al., Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. The Journal of Clinical Investigation 125 (2015), 3819–3830.
91. Gwathmey, J.K., Copelas, L., MacKinnon, R., Schoen, F.J., Feldman, M.D., Grossman, W. et al., Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circulation Research 61 (1987), 70–76.
92. Hamer, A.W., Arkles, L.B., Johns, J.A., Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: A placebo-controlled trial. Journal of the American College of Cardiology 14 (1989), 1768–1774.
93. Handschin, C., Spiegelman, B.M., The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 454 (2008), 463–469.
94. Hart, C.Y., Meyer, D.M., Tazelaar, H.D., Grande, J.P., Burnett, J.C. Jr., Housmans, P.R. et al., Load versus humoral activation in the genesis of early hypertensive heart disease. Circulation 104 (2001), 215–220.
95. van Heerebeek, L., Borbely, A., Niessen, H.W., Bronzwaer, J.G., van der Velden, J., Stienen, G.J. et al., Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113 (2006), 1966–1973.
96. van Heerebeek, L., Hamdani, N., Falcao-Pires, I., Leite-Moreira, A.F., Begieneman, M.P., Bronzwaer, J.G. et al., Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 126 (2012), 830–839.
97. Hirasaka, K., Lago, C.U., Kenaston, M.A., Fathe, K., Nowinski, S.M., Nikawa, T. et al., Identification of a redox-modulatory interaction between uncoupling protein 3 and thioredoxin 2 in the mitochondrial intermembrane space. Antioxidants & Redox Signaling 15 (2011), 2645–2661.
98. Hirsch, G.A., Bottomley, P.A., Gerstenblith, G., Weiss, R.G., Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. Journal of the American College of Cardiology 59 (2012), 802–808.
99. Holmstrom, K.M., Finkel, T., Cellular mechanisms and physiological consequences of redox-dependent signalling. Nature Reviews. Molecular Cell Biology 15 (2014), 411–421.
100. Holscher, M., Schafer, K., Krull, S., Farhat, K., Hesse, A., Silter, M. et al., Unfavourable consequences of chronic cardiac HIF-1alpha stabilization. Cardiovascular Research 94 (2012), 77–86.
101. Holubarsch, C.J., Rohrbach, M., Karrasch, M., Boehm, E., Polonski, L., Ponikowski, P. et al., A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: The ERGO (etomoxir for the recovery of glucose oxidation) study. Clinical Science (London, England) 113 (2007), 205–212.
102. Horowitz, J.D., Chirkov, Y.Y., Kennedy, J.A., Sverdlov, A.L., Modulation of myocardial metabolism: An emerging therapeutic principle. Current Opinion in Cardiology 25 (2010), 329–334.
103. Horowitz, J.D., Sia, S.T., Macdonald, P.S., Goble, A.J., Louis, W.J., Perhexiline maleate treatment for severe angina pectoris—Correlations with pharmacokinetics. International Journal of Cardiology 13 (1986), 219–229.
104. Howell, N.J., Ashrafian, H., Drury, N.E., Ranasinghe, A.M., Contractor, H., Isackson, H. et al., Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: Results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) trial. Circulation 123 (2011), 170–177.
105. Huang, W.P., Yin, W.H., Chen, J.W., Jen, H.L., Young, M.S., Lin, S.J., Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: An in vitro study. European Journal of Clinical Investigation 39 (2009), 775–783.
106. Huang, Q., Zhou, H.J., Zhang, H., Huang, Y., Hinojosa-Kirschenbaum, F., Fan, P. et al., Thioredoxin-2 inhibits mitochondrial reactive oxygen species generation and apoptosis stress kinase-1 activity to maintain cardiac function. Circulation 131 (2015), 1082–1097.
107. Hue, L., Taegtmeyer, H., The Randle cycle revisited: A new head for an old hat. American Journal of Physiology. Endocrinology and Metabolism 297 (2009), E578–591.
108. Hunter, W.G., Kelly, J.P., McGarrah, R.W. 3rd, Kraus, W.E., Shah, S.H., Metabolic dysfunction in heart failure: Diagnostic, prognostic, and pathophysiologic insights from metabolomic profiling. Current Heart Failure Reports 13 (2016), 119–131.
109. Hurd, T.R., Prime, T.A., Harbour, M.E., Lilley, K.S., Murphy, M.P., Detection of reactive oxygen species-sensitive thiol proteins by redox difference gel electrophoresis: Implications for mitochondrial redox signaling. The Journal of Biological Chemistry 282 (2007), 22040–22051.
110. Ide, T., Tsutsui, H., Kinugawa, S., Utsumi, H., Kang, D., Hattori, N. et al., Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circulation Research 85 (1999), 357–363.
111. Ingwall, J.S., The hypertrophied myocardium accumulates the MB-creatine kinase isozyme. European Heart Journal 5 (1984), 129–139 (Suppl F).
112. Iwanaga, Y., Nishi, I., Furuichi, S., Noguchi, T., Sase, K., Kihara, Y. et al., B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: Comparison between systolic and diastolic heart failure. Journal of the American College of Cardiology 47 (2006), 742–748.
113. Jackson, G., Gibbs, C.R., Davies, M.K., Lip, G.Y., ABC of heart failure. Pathophysiology. BMJ 320 (2000), 167–170.
114. Jameel, M.N., Xiong, Q., Mansoor, A., Bache, R.J., Zhang, J., ATP sensitive K(+) channels are critical for maintaining myocardial perfusion and high energy phosphates in the failing heart. Journal of Molecular and Cellular Cardiology 92 (2016), 116–121.
115. Jaswal, J.S., Keung, W., Wang, W., Ussher, J.R., Lopaschuk, G.D., Targeting fatty acid and carbohydrate oxidation—A novel therapeutic intervention in the ischemic and failing heart. Biochimica et Biophysica Acta 1813 (2011), 1333–1350.
116. Kalay, N., Ozdogru, I., Gul, A., Yucel, Y., Cetinkaya, Y., Inanc, M.T. et al., Effects of intermittent and long-term glucose-insulin-potassium infusion in patients with systolic heart failure. Experimental and Clinical Cardiology 13 (2008), 85–88.
117. Kantor, P.F., Lucien, A., Kozak, R., Lopaschuk, G.D., The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circulation Research 86 (2000), 580–588.
118. Karbowska, J., Kochan, Z., Smolenski, R.T., Peroxisome proliferator-activated receptor alpha is downregulated in the failing human heart. Cellular & Molecular Biology Letters 8 (2003), 49–53.
119. Kass, D.A., Maughan, W.L., Guo, Z.M., Kono, A., Sunagawa, K., Sagawa, K., Comparative influence of load versus inotropic states on indexes of ventricular contractility: Experimental and theoretical analysis based on pressure-volume relationships. Circulation 76 (1987), 1422–1436.
120. Kato, T., Niizuma, S., Inuzuka, Y., Kawashima, T., Okuda, J., Tamaki, Y. et al., Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circulation. Heart Failure 3 (2010), 420–430.
121. Kawashima, T., Inuzuka, Y., Okuda, J., Kato, T., Niizuma, S., Tamaki, Y. et al., Constitutive SIRT1 overexpression impairs mitochondria and reduces cardiac function in mice. Journal of Molecular and Cellular Cardiology 51 (2011), 1026–1036.
122. Kelly, R., Hayward, C., Avolio, A., O'Rourke, M., Noninvasive determination of age-related changes in the human arterial pulse. Circulation 80 (1989), 1652–1659.
123. Kelly, R.P., Ting, C.T., Yang, T.M., Liu, C.P., Maughan, W.L., Chang, M.S. et al., Effective arterial elastance as index of arterial vascular load in humans. Circulation 86 (1992), 513–521.
124. Kennedy, J.A., Beck-Oldach, K., McFadden-Lewis, K., Murphy, G.A., Wong, Y.W., Zhang, Y. et al., Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation. European Journal of Pharmacology 531 (2006), 13–19.
125. Kennedy, J.A., Kiosoglous, A.J., Murphy, G.A., Pelle, M.A., Horowitz, J.D., Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. Journal of Cardiovascular Pharmacology 36 (2000), 794–801.
126. Kennedy, J.A., Unger, S.A., Horowitz, J.D., Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochemical Pharmacology 52 (1996), 273–280.
127. Kim, T.T., Dyck, J.R., Is AMPK the savior of the failing heart?. Trends in Endocrinology and Metabolism 26 (2015), 40–48.
128. Kim, M., Platt, M.J., Shibasaki, T., Quaggin, S.E., Backx, P.H., Seino, S. et al., GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nature Medicine 19 (2013), 567–575.
129. Kitzman, D.W., Hundley, W.G., Brubaker, P.H., Morgan, T.M., Moore, J.B., Stewart, K.P. et al., A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: Effects on exercise tolerance and arterial distensibility. Circulation. Heart Failure 3 (2010), 477–485.
130. Kitzman, D.W., Little, W.C., Brubaker, P.H., Anderson, R.T., Hundley, W.G., Marburger, C.T. et al., Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288 (2002), 2144–2150.
131. Kober, L., Torp-Pedersen, C., McMurray, J.J., Gotzsche, O., Levy, S., Crijns, H. et al., Increased mortality after dronedarone therapy for severe heart failure. The New England Journal of Medicine 358 (2008), 2678–2687.
132. Kolobova, E., Tuganova, A., Boulatnikov, I., Popov, K.M., Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. The Biochemical Journal 358 (2001), 69–77.
133. Kolwicz, S.C. Jr., Airhart, S., Tian, R., Ketones step to the plate: A game changer for metabolic remodeling in heart failure?. Circulation 133 (2016), 689–691.
134. Kolwicz, S.C. Jr., Olson, D.P., Marney, L.C., Garcia-Menendez, L., Synovec, R.E., Tian, R., Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circulation Research 111 (2012), 728–738.
135. Krishnan, J., Suter, M., Windak, R., Krebs, T., Felley, A., Montessuit, C. et al., Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metabolism 9 (2009), 512–524.
136. Ky, B., French, B., May Khan, A., Plappert, T., Wang, A., Chirinos, J.A. et al., Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure. Journal of the American College of Cardiology 62 (2013), 1165–1172.
137. Labinskyy, V., Bellomo, M., Chandler, M.P., Young, M.E., Lionetti, V., Qanud, K. et al., Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure. The Journal of Pharmacology and Experimental Therapeutics 321 (2007), 165–171.
138. Lahey, R., Wang, X., Carley, A.N., Lewandowski, E.D., Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride. Circulation 130 (2014), 1790–1799.
139. Lam, V.H., Zhang, L., Huqi, A., Fukushima, A., Tanner, B.A., Onay-Besikci, A. et al., Activating PPARalpha prevents post-ischemic contractile dysfunction in hypertrophied neonatal hearts. Circulation Research 117 (2015), 41–51.
140. Langsjoen, P.H., Vadhanavikit, S., Folkers, K., Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proceedings of the National Academy of Sciences of the United States of America 82 (1985), 4240–4244.
141. Le Gall, J.Y., Guillouzo, A., Glaise, D., Deugnier, Y., Messner, M., Bourel, M., Perhexiline maleate toxicity on human liver cell lines. Gut 21 (1980), 977–984.
142. Lee, L., Campbell, R., Scheuermann-Freestone, M., Taylor, R., Gunaruwan, P., Williams, L. et al., Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment. Circulation 112 (2005), 3280–3288.
143. Lee, L., Horowitz, J., Frenneaux, M., Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. European Heart Journal 25 (2004), 634–641.
144. Lee, C.F., Tian, R., Mitochondrion as a target for heart failure therapy—Role of protein lysine acetylation. Circulation Journal 79 (2015), 1863–1870.
145. Lei, B., Lionetti, V., Young, M.E., Chandler, M.P., d'Agostino, C., Kang, E. et al., Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. Journal of Molecular and Cellular Cardiology 36 (2004), 567–576.
146. Lei, L., Mason, S., Liu, D., Huang, Y., Marks, C., Hickey, R. et al., Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Molecular and Cellular Biology 28 (2008), 3790–3803.
147. Lele, S.S., Macfarlane, D., Morrison, S., Thomson, H., Khafagi, F., Frenneaux, M., Determinants of exercise capacity in patients with coronary artery disease and mild to moderate systolic dysfunction. Role of heart rate and diastolic filling abnormalities. European Heart Journal 17 (1996), 204–212.
148. Lewis, J.F., DaCosta, M., Wargowich, T., Stacpoole, P., Effects of dichloroacetate in patients with congestive heart failure. Clinical Cardiology 21 (1998), 888–892.
149. Li, Y., Chen, C., Yao, F., Su, Q., Liu, D., Xue, R. et al., AMPK inhibits cardiac hypertrophy by promoting autophagy via mTORC1. Archives of Biochemistry and Biophysics 558 (2014), 79–86.
150. Li, P., Luo, S., Pan, C., Cheng, X., Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate. Molecular Medicine Reports 12 (2015), 7899–7906.
151. Li, Y.J., Wang, P.H., Chen, C., Zou, M.H., Wang, D.W., Improvement of mechanical heart function by trimetazidine in db/db mice. Acta Pharmacologica Sinica 31 (2010), 560–569.
152. Liberts, E.A., Willoughby, S.R., Kennedy, J.A., Horowitz, J.D., Effects of perhexiline and nitroglycerin on vascular, neutrophil and platelet function in patients with stable angina pectoris. European Journal of Pharmacology 560 (2007), 49–55.
153. Lindman, B.R., Davila-Roman, V.G., Mann, D.L., McNulty, S., Semigran, M.J., Lewis, G.D. et al., Cardiovascular phenotype in HFpEF patients with or without diabetes: A RELAX trial ancillary study. Journal of the American College of Cardiology 64 (2014), 541–549.
154. Lionetti, V., Linke, A., Chandler, M.P., Young, M.E., Penn, M.S., Gupte, S. et al., Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovascular Research 66 (2005), 454–461.
155. Lohse, M.J., G-protein-coupled receptor kinases and the heart. Trends in Cardiovascular Medicine 5 (1995), 63–68.
156. Lopaschuk, G.D., Belke, D.D., Gamble, J., Itoi, T., Schonekess, B.O., Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochimica et Biophysica Acta 1213 (1994), 263–276.
157. Lopaschuk, G.D., Ussher, J.R., Folmes, C.D., Jaswal, J.S., Stanley, W.C., Myocardial fatty acid metabolism in health and disease. Physiological Reviews 90 (2010), 207–258.
158. Lother, A., Hein, L., Pharmacology of heart failure: From basic science to novel therapies. Pharmacology & Therapeutics 166 (2016), 136–149.
159. Loudon, B.L., Noordali, H., Gollop, N.D., Frenneaux, M.P., Madhani, M., Present and future pharmacotherapeutic agents in heart failure: An evolving paradigm. British Journal of Pharmacology 173 (2016), 1911–1924.
160. Lu, T.M., Tsai, J.Y., Chen, Y.C., Huang, C.Y., Hsu, H.L., Weng, C.F. et al., Downregulation of Sirt1 as aging change in advanced heart failure. Journal of Biomedical Science, 21, 2014, 57.
161. Lu, Z., Xu, X., Hu, X., Fassett, J., Zhu, G., Tao, Y. et al., PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxidants & Redox Signaling 13 (2010), 1011–1022.
162. von Lueder, T.G., Sangaralingham, S.J., Wang, B.H., Kompa, A.R., Atar, D., Burnett, J.C. Jr. et al., Renin-angiotensin blockade combined with natriuretic peptide system augmentation: Novel therapeutic concepts to combat heart failure. Circulation. Heart Failure 6 (2013), 594–605.
163. Madsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., Matthews, D.R., Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 27 (2004), 1335–1342.
164. Maier, L.S., Layug, B., Karwatowska-Prokopczuk, E., Belardinelli, L., Lee, S., Sander, J. et al., RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: The RALI-DHF proof-of-concept study. JACC Heart Failure 1 (2013), 115–122.
165. Maldonado, E.N., Lemasters, J.J., ATP/ADP ratio, the missed connection between mitochondria and the Warburg effect. Mitochondrion 19 Pt A (2014), 78–84.
166. Mamas, M.A., Neyses, L., Fath-Ordoubadi, F., A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction. Experimental and Clinical Cardiology 15 (2010), e20–24.
167. Mann, D.L., Kent, R.L., Parsons, B., Cooper, G.t., Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85 (1992), 790–804.
168. Marti Masso, J.F., Marti, I., Carrera, N., Poza, J.J., Lopez de Munain, A., Trimetazidine induces parkinsonism, gait disorders and tremor. Thérapie 60 (2005), 419–422.
169. Masoud, W.G., Ussher, J.R., Wang, W., Jaswal, J.S., Wagg, C.S., Dyck, J.R. et al., Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation. Cardiovascular Research 101 (2014), 30–38.
170. Massie, B.M., Carson, P.E., McMurray, J.J., Komajda, M., McKelvie, R., Zile, M.R. et al., Irbesartan in patients with heart failure and preserved ejection fraction. The New England Journal of Medicine 359 (2008), 2456–2467.
171. Matsui, Y., Takagi, H., Qu, X., Abdellatif, M., Sakoda, H., Asano, T. et al., Distinct roles of autophagy in the heart during ischemia and reperfusion: Roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circulation Research 100 (2007), 914–922.
172. Mazue, G., Vic, P., Gouy, D., Remandet, B., Lacheretz, F., Berthe, J. et al., Recovery from amiodarone-induced lipidosis in laboratory animals: A toxicological study. Fundamental and Applied Toxicology 4 (1984), 992–999.
173. Mehta, S.R., Yusuf, S., Diaz, R., Zhu, J., Pais, P., Xavier, D. et al., Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. JAMA 293 (2005), 437–446.
174. Meier, C., Wahllaender, A., Hess, C.W., Preisig, R., Perhexiline-induced lipidosis in the dark Agouti (DA) rat. An animal model of genetically determined neurotoxicity. Brain 109:Pt 4 (1986), 649–660.
175. 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proceedings of the National Academy of Sciences of the United States of America 104 (2007), 19773–19777.
176. Milstien, S., Katusic, Z., Oxidation of tetrahydrobiopterin by peroxynitrite: Implications for vascular endothelial function. Biochemical and Biophysical Research Communications 263 (1999), 681–684.
177. Morgan, M.Y., Reshef, R., Shah, R.R., Oates, N.S., Smith, R.L., Sherlock, S., Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25 (1984), 1057–1064.
178. Morisco, C., Nappi, A., Argenziano, L., Sarno, D., Fonatana, D., Imbriaco, M. et al., Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: Effects of short-term coenzyme Q10 treatment. Molecular Aspects of Medicine 15:Suppl (1994), s155–163.
179. Mortensen, S.A., Rosenfeldt, F., Kumar, A., Dolliner, P., Filipiak, K.J., Pella, D. et al., The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: Results from Q-SYMBIO: A randomized double-blind trial. JACC Heart Fail 2 (2014), 641–649.
180. Munkholm, H., Hansen, H.H., Rasmussen, K., Coenzyme Q10 treatment in serious heart failure. BioFactors 9 (1999), 285–289.
181. Munzel, T., Gori, T., Keaney, J.F. Jr., Maack, C., Daiber, A., Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. European Heart Journal 36 (2015), 2555–2564.
182. Murray, A.J., Anderson, R.E., Watson, G.C., Radda, G.K., Clarke, K., Uncoupling proteins in human heart. Lancet 364 (2004), 1786–1788.
183. Murray, G.L., Colombo, J., Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure. Heart International 9 (2014), 66–73.
184. Nadruz, W. Jr., West, E., Santos, M., Skali, H., Groarke, J.D., Forman, D.E. et al., Heart failure and midrange ejection fraction: Implications of recovered ejection fraction for exercise tolerance and outcomes. Circulation. Heart Failure, 9, 2016, e002826.
185. Najjar, S.S., Schulman, S.P., Gerstenblith, G., Fleg, J.L., Kass, D.A., O'Connor, F. et al., Age and gender affect ventricular-vascular coupling during aerobic exercise. Journal of the American College of Cardiology 44 (2004), 611–617.
186. Nathanson, D., Ullman, B., Lofstrom, U., Hedman, A., Frick, M., Sjoholm, A. et al., Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: A double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 55 (2012), 926–935.
187. Neglia, D., De Caterina, A., Marraccini, P., Natali, A., Ciardetti, M., Vecoli, C. et al., Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. American Journal of Physiology. Heart and Circulatory Physiology 293 (2007), H3270–3278.
188. Nemoto, S., Fergusson, M.M., Finkel, T., Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306 (2004), 2105–2108.
189. Neri, R., Mestroni, L., Salvi, A., Pandullo, C., Camerini, F., Ventricular arrhythmias in dilated cardiomyopathy: Efficacy of amiodarone. American Heart Journal 113 (1987), 707–715.
190. Nesto, R.W., Bell, D., Bonow, R.O., Fonseca, V., Grundy, S.M., Horton, E.S. et al., Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108 (2003), 2941–2948.
191. Neubauer, S., The failing heart—An engine out of fuel. The New England Journal of Medicine 356 (2007), 1140–1151.
192. Neubauer, S., Horn, M., Cramer, M., Harre, K., Newell, J.B., Peters, W. et al., Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96 (1997), 2190–2196.
193. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86 (1992), 1810–1818.
194. Neubauer, S., Remkes, H., Spindler, M., Horn, M., Wiesmann, F., Prestle, J. et al., Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation 100 (1999), 1847–1850.
195. Ngo, D.T., Drury, N.E., Pagano, D., Frenneaux, M.P., Horowitz, J.D., Abstract 14461: How does perhexiline modulate myocardial energetics and ameliorate redox stress?. Circulation, 124, 2011, A14461.
196. Nicklas, J.M., McKenna, W.J., Stewart, R.A., Mickelson, J.K., Das, S.K., Schork, M.A. et al., Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. American Heart Journal 122 (1991), 1016–1021.
197. Nicolas-Robin, A., Amour, J., Ibanez-Esteve, C., Coriat, P., Riou, B., Langeron, O., Effect of glucose-insulin-potassium in severe acute heart failure after brain death. Critical Care Medicine 36 (2008), 2740–2745.
198. Obokata, M., Kane, G.C., Reddy, Y.N., Olson, T.P., Melenovsky, V., Borlaug, B.A., The role of diastolic stress testing in the evaluation for HFpEF: A simultaneous invasive-echocardiographic study. 2016 (Circulation).
199. O'Donnell, J.M., Fields, A.D., Sorokina, N., Lewandowski, E.D., The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. Journal of Molecular and Cellular Cardiology 44 (2008), 315–322.
200. Oka, S., Zhai, P., Yamamoto, T., Ikeda, Y., Byun, J., Hsu, C.P. et al., Peroxisome proliferator activated receptor-alpha association with silent information regulator 1 suppresses cardiac fatty acid metabolism in the failing heart. Circulation. Heart Failure 8 (2015), 1123–1132.
201. Oleck, S., Ventura, H.O., Coenzyme Q10 and utility in heart failure: Just another supplement?. Current Heart Failure Reports 13 (2016), 190–195.
202. Ono, H., Ohara, N., Hashimoto, K., Effect of an antianginal drug, perhexiline, on myocardial oxygen consumption in anesthetized open-chest dogs compared with verapamil and glyceryl trinitrate. Japanese Circulation Journal 46 (1982), 559–567.
203. Osorio, J.C., Stanley, W.C., Linke, A., Castellari, M., Diep, Q.N., Panchal, A.R. et al., Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 106 (2002), 606–612.
204. Owan, T.E., Hodge, D.O., Herges, R.M., Jacobsen, S.J., Roger, V.L., Redfield, M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction. The New England Journal of Medicine 355 (2006), 251–259.
205. Pacher, P., Liaudet, L., Bai, P., Virag, L., Mabley, J.G., Hasko, G. et al., Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. The Journal of Pharmacology and Experimental Therapeutics 300 (2002), 862–867.
206. Pacher, P., Szabo, C., Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: The therapeutic potential of PARP inhibitors. Cardiovascular Drug Reviews 25 (2007), 235–260.
207. Palacios, O.M., Carmona, J.J., Michan, S., Chen, K.Y., Manabe, Y., Ward, J.L. 3rd et al., Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging (Albany NY) 1 (2009), 771–783.
208. Paolisso, G., Gambardella, A., Galzerano, D., D'Amore, A., Rubino, P., Verza, M. et al., Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 43 (1994), 174–179.
209. Pascual, F., Coleman, R.A., Fuel availability and fate in cardiac metabolism: A tale of two substrates. Biochimica et Biophysica Acta 1860 (2016), 1425–1433.
210. Paul, M., Poyan Mehr, A., Kreutz, R., Physiology of local renin-angiotensin systems. Physiological Reviews 86 (2006), 747–803.
211. Paulus, W.J., Tschope, C., A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology 62 (2013), 263–271.
212. Pellieux, C., Aasum, E., Larsen, T.S., Montessuit, C., Papageorgiou, I., Pedrazzini, T. et al., Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway. Journal of Molecular and Cellular Cardiology 41 (2006), 459–466.
213. Phan, T.T., Abozguia, K., Nallur Shivu, G., Mahadevan, G., Ahmed, I., Williams, L. et al., Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. Journal of the American College of Cardiology 54 (2009), 402–409.
214. Phuong, H., Choi, B.Y., Chong, C.R., Raman, B., Horowitz, J.D., Can perhexiline be utilized without long-term toxicity? A clinical practice audit. Therapeutic Drug Monitoring 38 (2016), 73–78.
215. + depletion and reduced Sir2alpha deacetylase activity. The Journal of Biological Chemistry 280 (2005), 43121–43130.
216. Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J. et al., 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure 18 (2016), 891–975.
217. Prabu, S.K., Anandatheerthavarada, H.K., Raza, H., Srinivasan, S., Spear, J.F., Avadhani, N.G., Protein kinase A-mediated phosphorylation modulates cytochrome c oxidase function and augments hypoxia and myocardial ischemia-related injury. The Journal of Biological Chemistry 281 (2006), 2061–2070.
218. Price, N.L., Gomes, A.P., Ling, A.J., Duarte, F.V., Martin-Montalvo, A., North, B.J. et al., SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metabolism 15 (2012), 675–690.
219. Puigserver, P., Wu, Z., Park, C.W., Graves, R., Wright, M., Spiegelman, B.M., A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92 (1998), 829–839.
220. Randle, P.J., Garland, P.B., Hales, C.N., Newsholme, E.A., The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 (1963), 785–789.
221. Regitz, V., Bossaller, C., Strasser, R., Muller, M., Shug, A.L., Fleck, E., Metabolic alterations in end-stage and less severe heart failure—Myocardial carnitine decrease. Journal of Clinical Chemistry and Clinical Biochemistry 28 (1990), 611–617.
222. Revenco, D., Morgan, J.P., Metabolic modulation and cellular therapy of cardiac dysfunction and failure. Journal of Cellular and Molecular Medicine 13 (2009), 811–825.
223. Riehle, C., Wende, A.R., Zaha, V.G., Pires, K.M., Wayment, B., Olsen, C. et al., PGC-1beta deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Circulation Research 109 (2011), 783–793.
224. van Riet, E.E., Hoes, A.W., Wagenaar, K.P., Limburg, A., Landman, M.A., Rutten, F.H., Epidemiology of heart failure: The prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. European Journal of Heart Failure 18 (2016), 242–252.
225. Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., Puigserver, P., Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434 (2005), 113–118.
226. de Roos, A., Doornbos, J., Luyten, P.R., Oosterwaal, L.J., van der Wall, E.E., den Hollander, J.A., Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: Assessment with proton-decoupled P-31 MR spectroscopy. Journal of Magnetic Resonance Imaging 2 (1992), 711–719.
227. Rosca, M.G., Hoppel, C.L., Mitochondrial dysfunction in heart failure. Heart Failure Reviews 18 (2013), 607–622.
228. Sabbah, H.N., Gupta, R.C., Kohli, S., Wang, M., Hachem, S., Zhang, K., Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circulation. Heart Failure, 9, 2016, e002206.
229. Sack, M.N., Rader, T.A., Park, S., Bastin, J., McCune, S.A., Kelly, D.P., Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94 (1996), 2837–2842.
230. Samovski, D., Sun, J., Pietka, T., Gross, R.W., Eckel, R.H., Su, X. et al., Regulation of AMPK activation by CD36 links fatty acid uptake to beta-oxidation. Diabetes 64 (2015), 353–359.
231. Sander, S., Coleman, C.I., Patel, A.A., Kluger, J., White, C.M., The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. Journal of Cardiac Failure 12 (2006), 464–472.
232. Sarma, S., Ardehali, H., Gheorghiade, M., Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure. Heart Failure Reviews 17 (2012), 35–43.
233. Sasaki, H., Asanuma, H., Fujita, M., Takahama, H., Wakeno, M., Ito, S. et al., Metformin prevents progression of heart failure in dogs: Role of AMP-activated protein kinase. Circulation 119 (2009), 2568–2577.
234. Scheubel, R.J., Tostlebe, M., Simm, A., Rohrbach, S., Prondzinsky, R., Gellerich, F.N. et al., Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. Journal of the American College of Cardiology 40 (2002), 2174–2181.
235. Scheurle, C., Dammrich, M., Becker, J.U., Baumgartel, M.W., Renal phospholipidosis possibly induced by ranolazine. Clinical Kidney Journal 7 (2014), 62–64.
236. Schmidt-Schweda, S., Holubarsch, C., First clinical trial with etomoxir in patients with chronic congestive heart failure. Clinical Science (London, England) 99 (2000), 27–35.
237. Schonfeld, P., Wojtczak, L., Fatty acids decrease mitochondrial generation of reactive oxygen species at the reverse electron transport but increase it at the forward transport. Biochimica et Biophysica Acta 1767 (2007), 1032–1040.
238. Schrauwen, P., Saris, W.H., Hesselink, M.K., An alternative function for human uncoupling protein 3: Protection of mitochondria against accumulation of nonesterified fatty acids inside the mitochondrial matrix. The FASEB Journal 15 (2001), 2497–2502.
239. Schwartzenberg, S., Redfield, M.M., From, A.M., Sorajja, P., Nishimura, R.A., Borlaug, B.A., Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. Journal of the American College of Cardiology 59 (2012), 442–451.
240. Schwarz, K., Siddiqi, N., Singh, S., Neil, C.J., Dawson, D.K., Frenneaux, M.P., The breathing heart — Mitochondrial respiratory chain dysfunction in cardiac disease. International Journal of Cardiology 171 (2014), 134–143.
241. Shah, D.D., Fonarow, G.C., Horwich, T.B., Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. Journal of Cardiac Failure 16 (2010), 200–206.
242. Shah, S.J., Kitzman, D.W., Borlaug, B.A., van Heerebeek, L., Zile, M.R., Kass, D.A. et al., Phenotype-specific treatment of heart failure with preserved ejection fraction: A multiorgan roadmap. Circulation 134 (2016), 73–90.
243. Shah, R.R., Oates, N.S., Idle, J.R., Smith, R.L., Lockhart, J.D., Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. British Medical Journal (Clinical Research Ed.) 284 (1982), 295–299.
244. Sharma, N.M., Cunningham, C.J., Zheng, H., Liu, X., Patel, K.P., Hypoxia-inducible factor-1alpha mediates increased sympathoexcitation via glutamatergic N-methyl-D-aspartate receptors in the paraventricular nucleus of rats with chronic heart failure. Circ Heart Fail, 9, 2016.
245. Sharma, A., Fonarow, G.C., Butler, J., Ezekowitz, J.A., Felker, G.M., Coenzyme Q10 and heart failure: A state-of-the-art review. Circulation Heart Failure, 9, 2016, e002639.
246. Sharma, K., Kass, D.A., Heart failure with preserved ejection fraction: Mechanisms, clinical features, and therapies. Circulation Research 115 (2014), 79–96.
247. Shibayama, J., Yuzyuk, T.N., Cox, J., Makaju, A., Miller, M., Lichter, J. et al., Metabolic remodeling in moderate synchronous versus dyssynchronous pacing-induced heart failure: Integrated metabolomics and proteomics study. PloS One, 10, 2015, e0118974.
248. Siddiqi, N., Singh, S., Beadle, R., Dawson, D., Frenneaux, M., Cardiac metabolism in hypertrophy and heart failure: Implications for therapy. Heart Failure Reviews 18 (2013), 595–606.
249. Singh, A.P., Singh, R., Krishan, P., Ameliorative role of gemfibrozil against partial abdominal aortic constriction-induced cardiac hypertrophy in rats. Cardiology in the Young 25 (2015), 725–730.
250. Singh, S.N., Fletcher, R.D., Fisher, S.G., Singh, B.N., Lewis, H.D., Deedwania, P.C., Massie, B.M., Colling, C., Lazzeri, D., Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. New England Journal of Medicine 333:2 (1995), 77–82 (Jul 13).
251. Smith, C.S., Bottomley, P.A., Schulman, S.P., Gerstenblith, G., Weiss, R.G., Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 114 (2006), 1151–1158.
252. Sokos, G.G., Nikolaidis, L.A., Mankad, S., Elahi, D., Shannon, R.P., Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. Journal of Cardiac Failure 12 (2006), 694–699.
253. Solomon, S.D., Anavekar, N., Skali, H., McMurray, J.J., Swedberg, K., Yusuf, S. et al., Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112 (2005), 3738–3744.
254. Sorokina, N., O'Donnell, J.M., McKinney, R.D., Pound, K.M., Woldegiorgis, G., LaNoue, K.F. et al., Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation 115 (2007), 2033–2041.
255. Stanley, W.C., Recchia, F.A., Lopaschuk, G.D., Myocardial substrate metabolism in the normal and failing heart. Physiological Reviews 85 (2005), 1093–1129.
256. Stapel, B., Kohlhaas, M., Ricke-Hoch, M., Haghikia, A., Erschow, S., Knuuti, J. et al., Low STAT3 expression sensitizes to toxic effects of beta-adrenergic receptor stimulation in peripartum cardiomyopathy. European Heart Journal, 2016.
257. Sumimoto, T., Jikuhara, T., Hattori, T., Yuasa, F., Kaida, M., Hikosaka, M. et al., Importance of left ventricular diastolic function on maintenance of exercise capacity in patients with systolic dysfunction after anterior myocardial infarction. American Heart Journal 133 (1997), 87–93.
258. Sun, Y., Li, T., Xie, C., Zhang, Y., Zhou, K., Wang, X. et al., Dichloroacetate treatment improves mitochondrial metabolism and reduces brain injury in neonatal mice. Oncotarget 7 (2016), 31708–31722.
259. Sundaresan, N.R., Vasudevan, P., Zhong, L., Kim, G., Samant, S., Parekh, V. et al., The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nature Medicine 18 (2012), 1643–1650.
260. Suner, A., Cetin, M., The effect of trimetazidine on ventricular repolarization indexes and left ventricular diastolic function in patients with coronary slow flow. Coronary Artery Disease 27 (2016), 398–404.
261. Szeto, H.H., First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology 171 (2014), 2029–2050.
262. Tan, Y.T., Wenzelburger, F., Lee, E., Heatlie, G., Leyva, F., Patel, K. et al., The pathophysiology of heart failure with normal ejection fraction: Exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. Journal of the American College of Cardiology 54 (2009), 36–46.
263. Tang, Y., Mi, C., Liu, J., Gao, F., Long, J., Compromised mitochondrial remodeling in compensatory hypertrophied myocardium of spontaneously hypertensive rat. Cardiovascular Pathology 23 (2014), 101–106.
264. Tanno, M., Kuno, A., Yano, T., Miura, T., Hisahara, S., Ishikawa, S. et al., Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. The Journal of Biological Chemistry 285 (2010), 8375–8382.
265. Tenenbaum, A., Fisman, E.Z., Impaired glucose metabolism in patients with heart failure: Pathophysiology and possible treatment strategies. American Journal of Cardiovascular Drugs 4 (2004), 269–280.
266. Torp-Pedersen, C., Metra, M., Spark, P., Lukas, M.A., Moullet, C., Scherhag, A. et al., The safety of amiodarone in patients with heart failure. Journal of Cardiac Failure 13 (2007), 340–345.
267. Tsutsui, H., Kinugawa, S., Matsushima, S., Oxidative stress and heart failure. American Journal of Physiology. Heart and Circulatory Physiology 301 (2011), H2181–2190.
268. Turcani, M., Rupp, H., Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 96 (1997), 3681–3686.
269. Turcani, M., Rupp, H., Modification of left ventricular hypertrophy by chronic etomixir treatment. British Journal of Pharmacology 126 (1999), 501–507.
270. Tuunanen, H., Engblom, E., Naum, A., Nagren, K., Scheinin, M., Hesse, B. et al., Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 118 (2008), 1250–1258.
271. Unger, S.A., Kennedy, J.A., McFadden-Lewis, K., Minerds, K., Murphy, G.A., Horowitz, J.D., Dissociation between metabolic and efficiency effects of perhexiline in normoxic rat myocardium. Journal of Cardiovascular Pharmacology 46 (2005), 849–855.
272. Unger, S.A., Robinson, M.A., Horowitz, J.D., Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Australian and New Zealand Journal of Medicine 27 (1997), 24–28.
273. Ussher, J.R., Jaswal, J.S., Lopaschuk, G.D., Pyridine nucleotide regulation of cardiac intermediary metabolism. Circulation Research 111 (2012), 628–641.
274. Ventura-Clapier, R., Garnier, A., Veksler, V., Joubert, F., Bioenergetics of the failing heart. Biochimica et Biophysica Acta 1813 (2011), 1360–1372.
275. Vik-Mo, H., Mjos, O.D., Neely, J.R., Maroko, P.R., Ribeiro, L.G., Limitation of myocardial infarct size by metabolic interventions that reduce accumulation of fatty acid metabolites in ischemic myocardium. American Heart Journal 111 (1986), 1048–1054.
276. van der Vusse, G.J., van Bilsen, M., Glatz, J.F., Cardiac fatty acid uptake and transport in health and disease. Cardiovascular Research 45 (2000), 279–293.
277. Wang, C.H., Wang, S.S., Ko, W.J., Chen, Y.S., Chang, C.Y., Chang, R.W. et al., Acetyl-L-carnitine and oxfenicine on cardiac pumping mechanics in streptozotocin-induced diabetes in male Wistar rats. PloS One, 8, 2013, e69977.
278. Westermann, D., Lindner, D., Kasner, M., Zietsch, C., Savvatis, K., Escher, F. et al., Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circulation. Heart Failure 4 (2011), 44–52.
279. Worthley, M.I., Holmes, A.S., Willoughby, S.R., Kucia, A.M., Heresztyn, T., Stewart, S. et al., The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. Journal of the American College of Cardiology 49 (2007), 304–310.
280. Wroge, J., Williams, N.T., Glucagon-like peptide-1 (GLP-1) receptor agonists in cardiac disorders. The Annals of Pharmacotherapy 50 (2016), 1041–1050.
281. Wu, P., Peters, J.M., Harris, R.A., Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha. Biochemical and Biophysical Research Communications 287 (2001), 391–396.
282. Wu, H., Zhu, Q., Cai, M., Tong, X., Liu, D., Huang, J. et al., Effect of inhibiting malonyl-CoA decarboxylase on cardiac remodeling after myocardial infarction in rats. Cardiology 127 (2014), 236–244.
283. Xiao, H., Ma, X., Feng, W., Fu, Y., Lu, Z., Xu, M. et al., Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovascular Research 87 (2010), 504–513.
284. Xiong, Q., Zhang, P., Guo, J., Swingen, C., Jang, A., Zhang, J., Myocardial ATP hydrolysis rates in vivo: A porcine model of pressure overload-induced hypertrophy. American Journal of Physiology. Heart and Circulatory Physiology 309 (2015), H450–458.
285. Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E. Jr., Drazner, M.H. et al., 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 62 (2013), e147–239.
286. Yancy, C.W., Lopatin, M., Stevenson, L.W., De Marco, T., Fonarow, G.C., Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. Journal of the American College of Cardiology 47 (2006), 76–84.
287. Yao, H., Han, X., Han, X., The cardioprotection of the insulin-mediated PI3K/Akt/mTOR signaling pathway. American Journal of Cardiovascular Drugs 14 (2014), 433–442.
288. 123I BMIPP SPECT: Correlation with clinicopathological findings and clinical course. Heart 81 (1999), 153–159.
289. Yin, W.H., Chen, J.W., Chen, Y.H., Lin, S.J., Fenofibrate modulates HO-1 and ameliorates endothelial expression of cell adhesion molecules in systolic heart failure. Acta Cardiologica Sinica 29 (2013), 251–260.
290. Yin, X., Dwyer, J., Langley, S.R., Mayr, U., Xing, Q., Drozdov, I. et al., Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome. Journal of Molecular and Cellular Cardiology 55 (2013), 27–30.
291. Yin, M., van der Horst, I.C., van Melle, J.P., Qian, C., van Gilst, W.H., Sillje, H.H. et al., Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. American Journal of Physiology. Heart and Circulatory Physiology 301 (2011), H459–468.
292. Yoshioka, J., Chutkow, W.A., Lee, S., Kim, J.B., Yan, J., Tian, R. et al., Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. The Journal of Clinical Investigation 122 (2012), 267–279.
293. Yusuf, S., Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J. et al., Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 362 (2003), 777–781.
294. Zaha, V.G., Young, L.H., AMP-activated protein kinase regulation and biological actions in the heart. Circulation Research 111 (2012), 800–814.
295. Zander, M., Madsbad, S., Madsen, J.L., Holst, J.J., Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 359 (2002), 824–830.
296. Zhabyeyev, P., Gandhi, M., Mori, J., Basu, R., Kassiri, Z., Clanachan, A. et al., Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovascular Research 97 (2013), 676–685.
297. Zhang, L., Lu, Y., Jiang, H., Zhang, L., Sun, A., Zou, Y. et al., Additional use of trimetazidine in patients with chronic heart failure: A meta-analysis. Journal of the American College of Cardiology 59 (2012), 913–922.
298. 2 induced atrial fibrillation rats. Life Sciences 156 (2016), 7–14.